Evidence map›Paper›PMID 29744399›Full record

ReviewBioactive materials2016

Development of peptide inhibitors of HIV transmission.

Siyu Shi, Peter K Nguyen, Henry J Cabral, Ramon Diez-Barroso, Paul J Derry, Satoko M Kanahara, Vivek A Kumar

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Bioactive materials, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 30 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Cell-penetrating peptide inhibits retromer-mediated human papillomavirus trafficking during virus entry.Proceedings of the National Academy of Sciences of the United States of America · 2020
    Article
  16. Article
  17. Review
  18. Modelling Optimal Control of In-Host HIV Dynamics Using Different Control Strategies.Computational and mathematical methods in medicine · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Siyu ShiDepartment of Chemistry, Rice University, Houston, TX 77030, USA.
Peter K NguyenDepartment of Biomedical Engineering, New Jersey Institute of Technology, University Heights, Newark, NJ 07102, USA.
Henry J CabralDepartment of Biomedical Engineering, New Jersey Institute of Technology, University Heights, Newark, NJ 07102, USA.
Ramon Diez-BarrosoBaylor College of Medicine, Houston, TX 77030, USA.
Paul J DerryDepartment of Chemistry, Rice University, Houston, TX 77030, USA.
Satoko M KanaharaCommunity Healthcare Network, New York, NY 10010, USA.
Vivek A KumarDepartment of Biomedical Engineering, New Jersey Institute of Technology, University Heights, Newark, NJ 07102, USA.
New Jersey Institute of Technology · USRice University · USBaylor College of Medicine · USHealthCare Chaplaincy Network · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Treatment of HIV has long faced the challenge of high mutation rates leading to rapid development of resistance, with ongoing need to develop new methods to effectively fight the infection. Traditionally, early HIV medications were designed to inhibit RNA replication and protein production through small molecular drugs. Peptide based therapeutics are a versatile, promising field in HIV therapy, which continues to develop as we expand our understanding of key protein-protein interactions that occur in HIV replication and infection. This review begins with an introduction to HIV, followed by the biological basis of disease, current clinical management of the disease, therapeutics on the market, and finally potential avenues for improved drug development.

Indexed as

AIDS, acquired immunodeficiency syndromeART, antiretroviral therapyCDC, Centers for Disease Control and PreventionDrug developmentFDA, US Food and Drug AdministrationFY, fiscal yearHAART, highly active antiretroviral therapyHCV, hepatitis C VirusHIVHIV, human immunodeficiency virusHIV treatmentINSTI, Integrase strand transfer inhibitorsLEDGF, lens epithelium-derived growth factorNNRTI, Non-nucleoside reverse transcriptase inhibitorsNRTI, Nucleoside/Nucleotide Reverse Transcriptase InhibitorsPeptide inhibitorPeptide therapeuticR&D, research and developmentRT, reverse transcriptase

Identifiers

PMID29744399
PMCPMC5883972
OpenAlexW2519976792

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.